CTKB Q4 2024 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$553M

Q4 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$57M-1.3% YoY

Gross Profit

$34M58.5% margin

Operating Income

$3M5.2% margin

Net Income

$10M16.8% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+11.6%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$500M

Total Liabilities

$104M

Stockholders' Equity

$396M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$58M	-1.3%
Gross Profit	$34M	$33M	+1.8%
Operating Income	$3M	-$137,000	+2279.6%
Net Income	$10M	$6M	+75.2%

Revenue Segments

Product

$80M100%

Geographic Segments

UNITED STATES

$47M45%

EMEA

$30M29%

Asia Pacific

$20M20%

Other

$7M6%